Zhifei biological gets go-ahead for adolescent, adult vaccine trials

Chongqing Zhifei Biological Products Co., Ltd. (Zhifei Biological) announced that its wholly-owned subsidiary, Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd., has received clinical trial approval for its adsorbed acellular diphtheria, tetanus, and acellular pertussis (component) combined vaccine, designed for adults and adolescents. The National Medical Products Administration issued the approval, greenlighting trials to prevent infectious diseases caused by diphtheria, tetanus, and pertussis.

This vaccine represents a new generation of acellular pertussis, diphtheria, and tetanus vaccines, using purified active components. Currently, no approved vaccines specifically for adolescents and adults exist in China for these combined indications, suggesting a broad market opportunity. The company views this approval as a result of its focus on innovative technology and strengthened research and development.

Zhifei Biological emphasizes that this project, if successful, will enhance its multi-vaccine pipeline and strengthen its market competitiveness. The company will proceed with clinical trials as required by the approval, while reminding investors of the inherent risks associated with drug development, including high investment, long cycles, and potential uncertainties in trial outcomes and product launch.